Heparin and Suramin Alter Plitidepsin Uptake Via Inhibition of GPCR Coupled Signaling

REFERENCES

• Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, et al. Phase I study of Aplidine in a daily x5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 2006; 17: 1371–1378.
   Google Scholar
• Faivre S, Chieze S, Delbaldo C, Ady-vago N, Guzman C, Lopez-Lazaro L, et al. Phase I and pharmacokinetic study of ap-lidine, a new marine cyclodepsipeptide, in patients with advanced malignancies. J Clin Oncol. 2005; 23: 7780–2.
   PubMedGoogle Scholar
• Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by plitidepsine. Br J Cancer. 2002; 86 (9): 1510–7.
   PubMed Web of Science ®Google Scholar
• Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, et al. Plitidepsin, a new anticancer agent of marine ori-gin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (fit-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17 (1): 52–9
   PubMed Web of Science ®Google Scholar
• Erba E, Serafini M, Gaipa G, Tognon G, Marchini S, Celli N, et al. Effect of plitidepsin in acute lymphoblastic leukaemia cells. Br J Cancer. 2003; 89 (4): 763–73.
   PubMed Web of Science ®Google Scholar
• Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of plitidepsin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol. 2005; 16 (10): 1667–74.
   PubMed Web of Science ®Google Scholar
• Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Fair-cloth GT, et al. Antiangiogenic activity of plitidepsin, a new agent of marine origin. Br J Cancer. 2004; 90 (12): 2418–24.
   PubMed Web of Science ®Google Scholar
• Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, et al. Plitidepsin reduces growth of anaplastic thyroid can-cer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol. 2006; 57 (1): 7–14.
   PubMed Web of Science ®Google Scholar
• Gajate C, An F, Mollinedo F. Rapid and selective apopto-sis in human leukemic cells induced by plitidepsin through a fas/CD95- and mitochondrial-mediated mechanism. Clin Can-cer Res. 2003; 9 (4): 1535–45.
   PubMed Web of Science ®Google Scholar
• Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem. 2005;280 (12): 11641–7.
   PubMed Web of Science ®Google Scholar
• Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, et al. Plitidepsin induces apoptosis in human cancer cells via glutathione depletion and sustained acti-vation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem. 2003; 278 (1): 241–50.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Santiago L, Suarez Y, Zarich N, Munoz-Alonso MJ, Cuadrado A, Martinez T, et al. Plitidepsin induces JNK-de-pendent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Racl GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ. 2006; 13 (11): 1968–81.
   PubMed Web of Science ®Google Scholar
• Suarez Y, Gonzalez-Santiago L, Zarich N, Davalos A, Aranda JF, Alonso MA, et al. Plitidepsin cellular binding and Racl/JNK pathway activation depend on membrane cholesterol content. Mol Pharmacol. 2006; 70(5)4654-63.
   Google Scholar
• Humeniuk R, Menon LG, Saydam G, Longo-Sorbello GSA, Elisseyeff Y, Lewis LD et al. Plitidepsin synergizes with cy-tosine arabinoside: function'al relevance of mitochondria in pli-tidepsin induced cytotoxicity. Leukemia. 2007;21.2399-2405.
   Google Scholar
• Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem. 2002; 277 (32): 28364–7
   PubMed Web of Science ®Google Scholar
• Zhang XD, Deslandes E, Villedieu P, Poulain L, Duval M, Gauduchon P, et al. Effect of 2-deoxy-glucose on various malig-nant cell lines in vitro. Anticancer Res. 2006; 26( 5A)3561-6.
   Google Scholar
• Smolen JE, Kuczynski B, Koh EK, Balazovich KJ, Woronoff A. ‘Depletion’ of ATP by 2-deoxyglucose: secretion by electroporated human neutrophils is not restored by readdition of ATP. Neurosignals 1992; 1: 23–33.
   Google Scholar
• Martens JR, Sakamoto N, Sullivan SA, Grobaski TD, Tamkun MM. Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations. J Biol Chem 2001; 276 (11): 8409–14.
   PubMed Web of Science ®Google Scholar
• Conti M. Targeting K+ channels for cancer therapy. J Exp Ther Oncol. 2004; 4 (2): 161–6.
   PubMedGoogle Scholar
• Vink SR, van der Luit AH, Klarenbeek JB, Verheij M, van Blitterswijk WJ. Lipid rafts and metabolic energy differentially de-termine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biocheml Pharmacol 2007; 74: 145 6–1465.
   Google Scholar
• Cristillo AD, Xiao X, Campbell-Malone R, Dimitrov DS Bierer BE. Differences between CEM and human peripheral blood T lymphocytes in cAMP-dependent HIV viral fusion and CXCR4 expression. Exp Mol Pathol 2002; 73: 9–18.
   Google Scholar
• Lefkowitz RJ.G protein-coupled receptor kinases. Cell. 1993; 74 (3): 409–412.
   PubMed Web of Science ®Google Scholar
• Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez-AC, Mellado M. The chemokine SDF-lalpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999; 13 (13): 1699-710.
   PubMed Web of Science ®Google Scholar
• Chung WC, Kermode JC. Suramin disrupts receptor-G protein coupling by blocking association of Gprotein alpha and betagamma subunits. J Pharmacol Exp Ther 2005; 313 (1): 191-8. Epub 2004 Dec 30.
   Google Scholar
• Ferrand A, Kowalski-Chauvel A, Bertrand C, Escrieut C, Mathieu A, Portolan G, et al. A novel mechanism for JAK2 ac-tivation by a G protein-coupled receptor, the CCK2R:implica-tion of this signaling pathway in pancreatic tumor models. J Biol Chem 2005; 280 (11): 10710–5.)
   PubMed Web of Science ®Google Scholar
• Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, Hohenegger M, et al. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol. 1996; 49 (4): 602–11.
   PubMed Web of Science ®Google Scholar
• Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-can-cer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FESS Lett. 1989; 258 (1): 156–8.
   PubMed Web of Science ®Google Scholar
• Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal trans-ducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signaling proteins in plasmalemmal caveolae. Biochem J 2000; 351(Pt 1): 257–64.
   PubMedGoogle Scholar
• Kassack MU, Hogger P, Gschwend DA, Kameyama K, Haga T, Graul RC, et al. Molecular modeling of G-protein cou-pled receptor kinase 2: docking and biochemical evaluation of inhibitors. AAPS PharmSci. 2000;2(1):E2.
   PubMedGoogle Scholar
• Moriyama Y, Nelson N. Inhibition of vacuolar H+-AT-Pases by fusidic acid and suramin. FESS Lett. 1988; 234 (2): 383–6.
   PubMed Web of Science ®Google Scholar
• Ono K, Nakane H, Fukushima M. Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin. Eur J Biochem 1988; 172 (2): 349–53.
   PubMedGoogle Scholar
• Jindal HK, Anderson CW, Davis RG, Vishwanatha JK. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990; 50 (24): 7754–7.
   PubMed Web of Science ®Google Scholar
• von Kugelgen I. Pharmacological profiles of cloned mam-malian P2Y-receptor subtypes. Pharmacol Ther. 2006; 110 (3): 415–32.
   PubMed Web of Science ®Google Scholar
• Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934; 56: 658–666.
   Web of Science ®Google Scholar